April 2021

Data Collection in the Cancer Drugs Fund (CDF)

Since July 2016, the National Institute of Health and Care Excellence (NICE) has reviewed all new cancer drugs to determine whether they are clinically and cost-effective and should be routinely funded. If NICE can't make a robust decision based on existing evidence, they may make a recommendation for the drug to enter the CDF. The CDF allows additional data collection through ongoing clinical trials and routine clinical practice. The SACT data collection is designed to answer the identified uncertainties and allow a final funding recommendation to be made.

The table below displays the drugs in the CDF which are subject to an active SACT data collection and is updated monthly.

Drugs which are shown in yellow have an expected collection end date within the next 3 months.

*Please note that the dates shown in the expected data collection end date column are only indicative and may change depending on the appraisal requirements and/or trial results. Data is continuously collected throughout the data collection period as reports for NICE are produced periodically and therefore the expected data collection end date does not indicate the deadline for trusts to submit their data.

Drug	Company	Indication	Blueteq ID	Expected data collection end date*
Ibrutinib	Janssen	Waldenstrom's macroglobulinemia (relapsed/refractory to 1L)	IBR4	Sep-20
Ixazomib (with lenalidomide and dexamethasone)	Takeda	Multiple myeloma (relapsed/refractory 2L+)	IXA1	Oct-20
Daratumumab	Janssen	Multiple myeloma (relapsed/refractory, +3L)	DAR1	Nov-20
Venetoclax	AbbVie	CLL (17p del /TP53 mut - unsuitable/failed BCRi **OR** NO 17p del /TP53 mut failed chemoimmunotherapy AND BCRi	VEN1 - NO 17p del /TP53 mutation VEN2 - 17p del /TP53 mutation	Dec-20
Atezolizumab	Roche	Urothelial - advanced (1L - unsuitable for cisplatin therapy)	ATE1	Dec-20
Nivolumab with ipilimumab	BMS	Renal cell carcinoma	NIV9	Mar-21

Drug	Company	Indication	Blueteq ID	Expected data collection end date*
Pembrolizumab	MDS	adjuvant treatment of melanoma with high risk of recurrence	PEMB7	Mar-21
Durvalumab	AstraZeneca	NSCLC	DUR1	Jun-21
Palbociclib + fulvestrant	Pfizer	Metastatic, hormone-receptor positive, HER2-negative breast cancer after endocrine therapy	PAL2	Jun-21
Cemiplimab	Sanofi	Cutaneous squamous cell carcinoma	CEM1	Jul-21
Rucaparib	Clovis Oncology	Ovarian, fallopian tube and peritoneal cancer	RUC1, RUC2	Aug-21
Daratumumab with bortezomib	Janssen	Multiple myeloma (previously treated)	DAR2	Oct-21
Axicabtagene ciloleucel	Gilead/Kite	Diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies	AXI01a	Feb-22
Isatuximab (with pomalidomide and dexamethasone)	Sanofi	Multiple myeloma	ISA1_v1.0	Mar-22
Olaparib (with bevacizumab)	AstraZeneca	Ovarian, fallopian tube and primary peritoneal cancer	TBA	Mar-22
Pembrolizumab	MSD	Relapsed or refractory classical Hodgkin lymphoma	PEMB5	Jul-22
Venetoclax (with obinutuzumab)	AbbVie	Chronic lymphocytic leukaemia for subgroup with del(17p)/TP53 mutation for whom FCR or BR are suitable	VEN5_v1.0	Jan-23
Tisagenlecleucel	Novartis	Diffuse large B-cell lymphoma	TIS02a	Feb-23
Crizotinib	Pfizer	ROS1-positive advanced NSCLC (any line)	CRI3	Apr-23

Drug	Company	Indication	Blueteq ID	Expected data collection end date*
Tisagenlecleucel	Novartis	Relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years	IS01a	Jun-23
Larotrectinib	Bayer	NTRK fusion-positive solid tumours	LAR1a, LAR1b	Jul-23
Avelumab with axitinib	Merck and Pfizer	Untreated advanced renal cell carcinoma	AVE3_v1.0	Jul-23
Olaparib	AstraZeneca	Maintenance treatment of newly diagnosed BRCA-mutated advanced ovarian, fallopian tube or peritoneal cancer, after response to first-line platinum-based chemotherapy	OLAP1a	Dec-23
KTE-X19	Gilead	Mantle cell lymphoma	KTE01a_v1.0	Dec-23
Niraparib	GSK	Ovarian, fallopian tube and primary peritoneal cancer	NIR1_v2.1	Dec-24
Entrectinib	Roche	NTRK fusion-positive solid tumours	ENT1a_v1.0, ENT1b_v1.0	Mar-26